Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States

Despite racial and ethnic minorities bearing a disproportionate burden of moderate-to-severe AD, they are underrepresented in clinical trials and face documented barriers to accessing advanced systemic therapies. The real-world magnitude of these disparities—and whether they persist after controlling for disease severity and clinical factors—had not been quantified in a large US prospective registry.

The TARGET-DERM AD registry was used to compare disease severity, comorbidities, and advanced systemic therapy utilization rates across Non-Hispanic White, Non-Hispanic Black, Hispanic, and Non-Hispanic Asian patient groups, with multivariable analyses adjusting for relevant clinical and demographic confounders.

Demonstrating persistent disparities in advanced therapy access by race and ethnicity—even after clinical adjustment—provides actionable evidence for health equity initiatives in AD care, supports FDA diversity requirements for clinical trial enrollment, and directly informs AbbVie's market access and commercial strategy for its AD portfolio.

Racial and ethnic disparity quantification in advanced AD therapy access for health equity and regulatory strategy, Real-world treatment utilization gap analysis supporting diverse enrollment requirements, Evidence base for payer and policy advocacy around equitable access to advanced AD therapies